MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
1.210
-0.030
-2.42%
Pre Market: 1.250 +0.04 +3.31% 04:14 05/11 EDT
OPEN
1.250
PREV CLOSE
1.240
HIGH
1.250
LOW
1.205
VOLUME
3.23K
TURNOVER
0
52 WEEK HIGH
2.610
52 WEEK LOW
0.7362
MARKET CAP
228.25M
P/E (TTM)
-9.9917
1D
5D
1M
3M
1Y
5Y
1D
Here are the major earnings before the open Monday
Seeking Alpha · 13h ago
Heron Therapeutics Q1 2026 Earnings Preview
Seeking Alpha · 2d ago
Weekly Report: what happened at HRTX last week (0427-0501)?
Weekly Report · 05/04 09:40
Heron Therapeutics to report first-quarter results, host conference call and webcast
PUBT · 04/27 21:30
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Barchart · 04/27 16:30
Weekly Report: what happened at HRTX last week (0420-0424)?
Weekly Report · 04/27 09:40
Weekly Report: what happened at HRTX last week (0413-0417)?
Weekly Report · 04/20 09:39
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
TipRanks · 04/16 19:15
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Webull offers Heron Therapeutics Inc stock information, including NASDAQ: HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.